Loading...
•
Dec 31, 2022
Amedisys Q4 2022 Earnings Report
Amedisys's financial performance remained relatively stable in Q4 2022 compared to the previous year. Net service revenue and net income saw slight decreases, while the company announced the sale of its Personal Care line of business and a new palliative care partnership.
Key Takeaways
Amedisys reported a slight increase in net service revenue to $562.0 million for Q4 2022, compared to $559.3 million in 2021. Net income attributable to Amedisys, Inc. was $31.7 million, slightly lower than the $34.0 million reported in the same period last year. The company also announced the sale of its personal care line of business and a palliative care partnership with BlueCross BlueShield of Tennessee.
Net service revenue increased slightly to $562.0 million compared to $559.3 million in the same period last year.
Net income attributable to Amedisys, Inc. decreased to $31.7 million from $34.0 million in 2021.
Adjusted EBITDA was $59.9 million, compared to $64.8 million in 2021.
The company announced the sale of its personal care line of business and a new palliative care partnership with BlueCross BlueShield of Tennessee.
Amedisys
Amedisys
Forward Guidance
Amedisys anticipates adjusted net service revenue to be in the range of $2.244 billion to $2.274 billion, adjusted EBITDA in the range of $230 million to $240 million, and adjusted diluted earnings per share in the range of $4.13 to $4.36 for 2023.
Positive Outlook
- Adjusted net service revenue is anticipated to be in the range of $2.244 billion to $2.274 billion.
- Adjusted EBITDA is anticipated to be in the range of $230 million to $240 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $4.13 to $4.36.
- Guidance is based on an estimated 32.9 million shares outstanding.
- The company is focused on people, growth, clinical optimization and Contessa which will pay dividends as we progress throughout 2023.
Challenges Ahead
- Guidance excludes the effects of any future acquisitions.
- Guidance excludes potential share repurchases.
- The home health, hospice, personal care and high acuity care industries are highly competitive.
- The industries are subject to intensive regulations.
- Trends are subject to numerous factors, risks, and uncertainties.